Category: Edwards Lifesciences
James Mazzo and Versant Ventures agree to suspend Mazzo after his indictment on insider trading charges stemming from Abbott's $2.8 billion acquisition of Advanced Medical Optics.
Versant Ventures and James Mazzo agreed that Mazzo will "suspend any activities" at the venture capital shop following his indictment last month on insider trading charges.
Here's a look at some of the top Wall Street stories for medical device companies this week: Wall Street loves Edwards Lifesciences again; Becton Dickinson to buy CareFusion for $12 billion in cash, stock; Proxy war rages on at Echo Therapeutics; Platinum fires back at Echo Therapeutics over 'rogue' directors; Echo Therapeutics hits back at Platinum Equity
Allergan CEO David Pyott steps down from the board at Edwards Lifesciences to devote more time to his chief executive duties.
, Boston Scientific
, Edwards Lifesciences
, LensAR Inc.
, LifeCell Corp.
, Polaris Industries
, Premier Inc.
, Sensory Medical
, STAAR Surgical Co.
, Thoratec Corp.
, Allergan Inc.
Edwards Lifesciences is flirting with all time highs on The Street after nearly 2 years of bearish results.
Edwards Lifesciences (NYSE:EW) is back in Wall Street's good graces, with shares of the Irvine, Calif.-based heart valve maker approaching all time highs after nearly 2 years of down performance.
The Sapien 3 replacement heart valve made by Edwards Lifesciences is poised to take the lead in the market for transcatheter aortic valve implants, according to one analyst.
MASSDEVICE ON CALL — Edwards Lifesciences (NYSE:EW) is poised to take the lead in the transcatheter aortic valve market with its Sapient 3 replacement heart valve, according to Leerink Partners analyst Danielle Antalffy.
Researchers recommend quick surgery for patients with severe symptomatic aortic stenosis
NEW YORK (Reuters Health) - Patients with severe symptomatic aortic stenosis who need aortic valve replacement should have the surgery as soon as possible, new research suggests.
"Our research highlights the importance of treating aortic stenosis in a timely fashion. Delays lead to unnecessary risk and patients should ideally have an aortic valve replacement within a month of diagnosis," Dr. Chris Malaisrie of Northwestern University, Feinberg School of Medicine, in Chicago, Illinois, told Reuters Health by email.
Edwards Lifesciences CEO Michael Mussallem discusses the company's recent FDA win for the Sapien replacement heart valve in this 2011 interview with MassDevice publisher Brian Johnson